Cancer vaccines: Can they improve survival?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 30, Issue 4, 2015, Pages 147-151

  Dillman, Robert O ^a  

^a Caladrius Biosciences   (United States)

Author keywords

cancer vaccines; melanoma; overall survival; prostate cancer

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ELTRAPULDENCEL T; IPILIMUMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TUMOR ANTIGEN; MONOCLONAL ANTIBODY; TISSUE EXTRACT;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; IMMUNOLOGY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MALE; MELANOMA; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE EXTRACTS;

EID: 84928956390     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1805     Document Type: Article

References (44)

1. Dillman RO. Cancer Immunotherapy. Cancer Biother Radiopharm 2011; 1: 1.
2. Dillman RO. Melanoma Vaccines: Trials and Tribulations. Vaccine Dev Ther 2013; 3: 57.
3. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25: 474s (abstr 8508
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711.
5. Levy R, Ganjoo KN, Leonard JP, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 2014; 32: 1797.
6. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 2012; 104: 599.
7. Dillman RO, Cornforth AN, Nistor G. Cancer stem cell antigen-based vaccines: The preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opin Biol Ther 2013; 13: 643.
8. Hersey P, Gallagher S. Intralesional immunotherapy of melanoma. J Surg Oncol 2014; 109: 320.
9. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Cancer Rev 2012; 12: 252.
10. Dillman RO. Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials. Cancer Biother Radiopharm 1996; 11: 99.
11. Oldham R, Dillman R. Gold standard or wrong standard?. Cancer Biother Radiopharm 2004; 19: 271.
12. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6: 1163.
13. Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 17: 359.
14. Dillman RO. Patient-specific therapeutic vaccines for metastatic melanoma. Oncology Issues 2015; March-April: 48.
15. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic Tlymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614.
16. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189.
17. Small EJ, Schellhammer PF, Higano CA, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089.
18. Higano CS, Scjhellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670.
19. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17: 4558.
20. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411.
21. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-Targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099.
22. Stein WD, Gulley J, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17: 907.
23. Dillman RO, DePriest C, De Leon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007; 22: 309.
24. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993; 71: 2358.
25. Dillman RO, Weimann MC, Vander Molen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm 1997; 12: 249.
26. Edge SE, Byrd DR, Compton CC, et al. Chapter 31 Melanoma of the Skin. In: Cancer Staging Handbook 7th ed. New York: Springer, 2010; 387-416.
27. Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: Final Report. Cancer Biother Radiopharm 2009; 24: 311.
28. Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med 2006; 355: 1179.
29. Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012; 35: 641.
30. Dillman RO, Nanci AA, Williams ST, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm 2010; 25: 553.
31. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355.
32. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174.
33. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA 2014; 312: 1744.
34. Topalian SL, Hodi S, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443.
35. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134.
36. Robert C, Ribas A, Wolchok JD, et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomized dose-comparison cohort of a phase I trial. Lancet 2014; 384: 1109.
37. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020.
38. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320.
39. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 2013; 499: 214.
40. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747.
41. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer. Science 2014; 344: 641.
42. Lu Y-C, Yao X, Crystal JS, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 2014; 20: 3401.
43. Guidance for Industry: Clinical trial endpoints for the approval of cancer drugs and biologics. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) 2007; 1-22.
44. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27: 2874.